Purdue and Oxycontin is a true example of a scenario of major failure with the FDA.
But Purdue falsely said it was a non addictive alternative to addictive opiods. And marketed the hell out of it. Lying ****s!
Yet the FDA approved the drug after their approval process.
Knowingly or niavely, and were very very sloooow in any push back when mounting evidence showed it was creating a disaster of addiction.
Re: Retts - Currently there is no approved treatment for Retts, nor one likely for quite some time.
It is not a replacement or competitor drug treatment. It will be the only treatment, IF approved.
The only decisions the FDA need to make are:
Does it give benefit to the sufferers?
Do the positives outweigh the negatives?
Does the treatment do harm to the sufferers?
.
I am not the FDA.
But from all info I have seen, the answers to those questions should be:
Yes
Yes
No
.
- Forums
- ASX - By Stock
- NEU
- Ann: Rett Syndrome NDA accepted for Priority Review by FDA
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.99%
!
$12.04

Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-111
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.04 |
Change
-0.500(3.99%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.45 | $12.45 | $11.88 | $1.226M | 101.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 121 | $12.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.04 | 507 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 403 | 11.910 |
5 | 2759 | 11.900 |
3 | 820 | 11.890 |
5 | 3725 | 11.880 |
4 | 1281 | 11.870 |
Price($) | Vol. | No. |
---|---|---|
11.930 | 419 | 6 |
11.940 | 434 | 3 |
11.950 | 900 | 5 |
11.960 | 1439 | 5 |
11.970 | 1624 | 6 |
Last trade - 10.28am 23/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |